Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

522
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
522
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

142
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
142
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

130
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
130
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

37
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
37
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

66
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
66

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of non-selective beta-blockers on acute kidney injury outcomes in patients with decompensated cirrhosis.

Journal of hepatology·2026
Same author

Pre-Treatment Serum Albumin Concentration Predicts Clinical Benefit of Long-Term Albumin in Patients With Cirrhosis and Ascites.

United European gastroenterology journal·2026
Same author

Pre-liver transplant assessment of patients with acute-on-chronic liver failure: An international survey.

JHEP reports : innovation in hepatology·2026
Same author

Long Term Follow-Up After Transplantation in Propionic Acidemia: A Retrospective French Pediatric and Adult Cohort Study.

Journal of inherited metabolic disease·2026
Same author

Moving Forward in HRS - Treatments and Definitions.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Liver Transplantation for HBV-Related Disease in France: NUC Type Before LT Is Associated With Patient Survival.

Liver international : official journal of the International Association for the Study of the Liver·2026

Related Experiment Video

Updated: May 5, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

15.9K

Simvastatin and Rifaximin in Decompensated Cirrhosis: A Randomized Clinical Trial.

Elisa Pose1,2,3, César Jiménez4,5, Giacomo Zaccherini6,7

  • 1Liver Unit, Hospital Clínic de Barcelona, Barcelona, Spain.

JAMA
|February 5, 2025
PubMed
Summary

Simvastatin and rifaximin combination therapy did not improve outcomes for patients with decompensated liver cirrhosis. This trial found no significant reduction in severe complications, organ failure, or mortality compared to placebo.

More Related Videos

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

23.0K
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

13.0K

Related Experiment Videos

Last Updated: May 5, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

15.9K
Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

23.0K
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

13.0K

Area of Science:

  • Hepatology
  • Clinical Trials
  • Pharmacology

Background:

  • Liver cirrhosis complications significantly impact patient outcomes.
  • Current treatments lack efficacy in preventing severe cirrhotic complications.
  • Simvastatin and rifaximin have individually shown potential benefits in liver cirrhosis.

Purpose of the Study:

  • To evaluate the efficacy of combining simvastatin and rifaximin in improving outcomes for patients with decompensated cirrhosis.
  • To assess the impact of this combination therapy on severe complications and mortality.

Main Methods:

  • A phase 3, double-blind, placebo-controlled trial involving 237 patients with decompensated cirrhosis across 14 European hospitals.
  • Patients received standard therapy plus either simvastatin (20 mg/d) and rifaximin (1200 mg/d) or placebo for 12 months.
  • Primary endpoint was the incidence of acute-on-chronic liver failure; secondary endpoints included transplant-free survival and composite cirrhosis complications.

Main Results:

  • No significant difference was observed in the incidence of acute-on-chronic liver failure between the simvastatin-rifaximin group (17.9%) and the placebo group (14.2%).
  • Transplant or death rates (18.8% vs 24.2%) and the development of cirrhosis complications (42.7% vs 45.8%) were also similar between groups.
  • Adverse events were comparable, though three patients in the treatment group experienced rhabdomyolysis.

Conclusions:

  • The combination of simvastatin and rifaximin, when added to standard therapy, does not improve clinical outcomes in patients with decompensated liver cirrhosis.
  • Further research may be needed to explore alternative therapeutic strategies for this patient population.